The following TCI research programs were highlighted in the NCI application and commended for their strong foundation and national acclaim:
Cancer Immunology, led by Nina Bhardwaj, MD, PhD and Miriam Merad, MD, PhD, which addresses anti-tumor immunity and fosters the development of cancer vaccines;
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
Cancer Mechanisms, led by Ramon Parsons, MD, PhD and Ross Cagan, PhD, which seeks to understand the biology of cancer cell development;
Liver Cancer, led by Scott Friedman, MD and Josep Llovet, MD, whose focus is to discover novel approaches to diagnose and treat liver cancer; and
Cancer Prevention and Control, led by Paolo Boffetta, MD, MPH and William Redd, PhD, which addresses the important aspects of primary and secondary cancer prevention.
“The Tisch Cancer Institute at Mount Sinai reflects a vital trend seen in recent years: real world, complex medical problems being solved by teams that successfully integrate many disciplines,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs for the Mount Sinai Health System. “The NCI designation is based on our exceptional leadership, extensive research facilities, and an institution-wide commitment to research, including a focus on the role of genetics, obesity, and diabetes in cancer. The NCI designation will facilitate expansion of novel treatment options and clinical trials for patients throughout the Mount Sinai Health System.”
“Congratulations to Dr. Burakoff and the entire Mount Sinai team for receiving this prestigious designation,” said U.S. Senator Charles E. Schumer (D-NY). “It recognizes Mount Sinai’s deep commitment to offering the newest and most sophisticated therapies in the prevention, diagnosis, and treatment of cancer.”
“I congratulate Mount Sinai for earning this prestigious honor,” said U.S. Representative Charles B. Rangel (D-NY). “Mount Sinai has been instrumental in improving the health of our communities in East and Central Harlem. This designation reinforces Mount Sinai’s role as a tremendous asset for those battling cancer in our community.”
“I applaud the recent announcement by the National Cancer Institute that Mount Sinai will receive an $8.5 million grant over the next five years,” said U.S. Representative Carolyn Maloney (D-NY). “This investment reflects Mount Sinai's commitment to finding a cure and providing the highest level of care and treatment for the people of New York and the many patients who travel to our state for advanced care. Thank you to the dedicated team and support staff at Mount Sinai for improving options for those affected by cancer.”
